enVVeno Secures New Patent for Core Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Patent Protection Strengthened: enVVeno Medical Corporation has been granted U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio for the enVVe® transcatheter replacement venous valve system, covering key components such as the valve and support frame, thereby enhancing its competitive position in a multi-billion-dollar market.
- FDA Approval Milestone: The company has received its first FDA IDE approval, marking the imminent launch of pivotal trials for a non-surgical replacement venous valve, with the first patient data expected by the end of Q4 2026, showcasing the potential of its clinical research and market prospects.
- Therapeutic Innovation: The enVVe system aims to provide a non-surgical, catheter-based alternative that reduces invasiveness, eliminates the need for general anesthesia and overnight hospital stays, and is expected to broaden access to treatment for patients with deep venous insufficiency.
- Market Leadership Position: With the issuance of the patent and FDA approval, enVVeno further solidifies its leadership in the field of replacement venous valve therapy, anticipating that its innovative technology will transform the treatment of chronic venous insufficiency and create long-term growth opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVNO
About NVNO
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
enVVeno Secures New Patent for Core Technology
- Patent Protection Strengthened: enVVeno Medical Corporation has been granted U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio for the enVVe® transcatheter replacement venous valve system, covering key components such as the valve and support frame, thereby enhancing its competitive position in a multi-billion-dollar market.
- FDA Approval Milestone: The company has received its first FDA IDE approval, marking the imminent launch of pivotal trials for a non-surgical replacement venous valve, with the first patient data expected by the end of Q4 2026, showcasing the potential of its clinical research and market prospects.
- Therapeutic Innovation: The enVVe system aims to provide a non-surgical, catheter-based alternative that reduces invasiveness, eliminates the need for general anesthesia and overnight hospital stays, and is expected to broaden access to treatment for patients with deep venous insufficiency.
- Market Leadership Position: With the issuance of the patent and FDA approval, enVVeno further solidifies its leadership in the field of replacement venous valve therapy, anticipating that its innovative technology will transform the treatment of chronic venous insufficiency and create long-term growth opportunities.
See More
enVVeno Secures First FDA IDE Approval for Pivotal Study
- First FDA IDE Approval: enVVeno Medical has received the FDA's first-ever IDE approval, allowing it to conduct a pivotal study on a non-surgical replacement venous valve, marking a significant advancement in the treatment of deep venous disease.
- Market Impact Potential: This study targets approximately 3 million U.S. patients suffering from Deep Venous Insufficiency (DVI), and if successful, it could provide the first effective treatment option, significantly improving patient quality of life.
- Innovative Medical Device: The enVVe system being developed by enVVeno is a first-in-class non-surgical replacement venous valve designed to be implanted via catheter under light sedation, reducing hospital stay and enhancing patient experience.
- Strategic Development Direction: This FDA approval not only provides strong support for enVVeno's product development but may also attract more investor interest, driving the company's further expansion in the medical device market.
See More
enVVeno Medical Receives FDA Approval for TAVVE Trial
- First IDE Approval: enVVeno Medical has received the first-ever IDE approval from the FDA to conduct the TAVVE® trial, evaluating its innovative enVVe® system aimed at providing the first effective treatment option for approximately 3 million U.S. patients suffering from severe Chronic Venous Insufficiency (CVI), marking a significant advancement in the treatment of deep venous diseases.
- Clinical Trial Scale: The TAVVE trial will be conducted in two phases, with the first phase enrolling 10 patients for a 30-day safety assessment, followed by a second phase enrolling 220 patients, with 165 receiving the enVVe valve and 55 in a control group, expected to provide critical safety and efficacy data to the FDA.
- Significant Market Potential: With U.S. healthcare costs exceeding $20 billion annually due to deep venous insufficiency, the introduction of the enVVe system not only addresses this substantial unmet clinical need but also opens up a multi-billion-dollar market opportunity for the company, enhancing its competitiveness in the medical device sector.
- Sufficient Funding for Operations: As of March 31, 2026, enVVeno has approximately $25 million in cash and investments, which is expected to fund operations into Q3 2027, providing financial support for the successful execution of the TAVVE trial.
See More
enVVeno Medical Reports FY GAAP EPS of -$33.06 Amid Reverse Stock Split
- Poor Financial Performance: enVVeno Medical reported a FY GAAP EPS of -$33.06, indicating significant challenges in financial health that could lead to a decline in investor confidence.
- Reverse Stock Split Announcement: The company announced a reverse stock split aimed at boosting its share price to meet exchange listing requirements; however, this move failed to improve market sentiment, resulting in a 20% drop in share price.
- Negative Market Reaction: Following the reverse split, the stock price fell by 20%, reflecting investor concerns about the company's future prospects, which may impact its ability to raise capital and maintain market competitiveness.
- Need for Strategic Reevaluation: Given the current financial situation, the company must reassess its strategic direction to address ongoing losses and restore investor trust, ensuring sustainable growth in the future.
See More
enVVeno Medical Approves 1-for-35 Reverse Stock Split, Reducing Shares to 655K
- Reverse Stock Split Decision: enVVeno Medical's board approved a 1-for-35 reverse stock split effective January 20, 2026, reducing outstanding shares from approximately 22.9 million to about 655,000, aiming to enhance share price and attract investor interest.
- Exchange Arrangement: Post-split, the company's common stock will resume trading on the Nasdaq Capital Market under the existing ticker symbol 'NVNO', indicating a strategic move to improve market perception and liquidity.
- Market Reaction: Following the reverse split announcement, enVVeno Medical's stock price fell 19.69% in premarket trading to $0.2761, reflecting negative market sentiment that could impact investor confidence.
- Shareholder Impact: The reverse split will consolidate every 35 shares into one, which may reduce the number of shares held by shareholders in the short term, but the company aims to improve long-term investment appeal through a higher share price.
See More
Gold Drops More Than 2%; Cidara Therapeutics Stock Soars
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling 0.44%, while the NASDAQ and S&P 500 rose by 0.59% and 0.27%, respectively. Utilities shares increased slightly, but communication services stocks dropped by 1%.
Notable Company Performances: Spire Inc's shares fell over 2% after reporting larger-than-expected quarterly losses, while Cidara Therapeutics saw a 105% surge in shares following Merck's acquisition announcement.
Commodities Update: Oil prices rose by 1.9% to $59.81, while gold and silver prices fell by 2.2% and 5%, respectively. Copper also saw a decline of 1.1%.
Global Market Trends: European shares declined, with the STOXX 600 down 1.54%, and Asian markets mostly closed lower, highlighted by Japan's Nikkei 225 dropping 1.77%.
See More
enVVeno Secures New Patent for Core Technology
- Patent Protection Strengthened: enVVeno Medical Corporation has been granted U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio for the enVVe® transcatheter replacement venous valve system, covering key components such as the valve and support frame, thereby enhancing its competitive position in a multi-billion-dollar market.
- FDA Approval Milestone: The company has received its first FDA IDE approval, marking the imminent launch of pivotal trials for a non-surgical replacement venous valve, with the first patient data expected by the end of Q4 2026, showcasing the potential of its clinical research and market prospects.
- Therapeutic Innovation: The enVVe system aims to provide a non-surgical, catheter-based alternative that reduces invasiveness, eliminates the need for general anesthesia and overnight hospital stays, and is expected to broaden access to treatment for patients with deep venous insufficiency.
- Market Leadership Position: With the issuance of the patent and FDA approval, enVVeno further solidifies its leadership in the field of replacement venous valve therapy, anticipating that its innovative technology will transform the treatment of chronic venous insufficiency and create long-term growth opportunities.
See More
enVVeno Secures First FDA IDE Approval for Pivotal Study
- First FDA IDE Approval: enVVeno Medical has received the FDA's first-ever IDE approval, allowing it to conduct a pivotal study on a non-surgical replacement venous valve, marking a significant advancement in the treatment of deep venous disease.
- Market Impact Potential: This study targets approximately 3 million U.S. patients suffering from Deep Venous Insufficiency (DVI), and if successful, it could provide the first effective treatment option, significantly improving patient quality of life.
- Innovative Medical Device: The enVVe system being developed by enVVeno is a first-in-class non-surgical replacement venous valve designed to be implanted via catheter under light sedation, reducing hospital stay and enhancing patient experience.
- Strategic Development Direction: This FDA approval not only provides strong support for enVVeno's product development but may also attract more investor interest, driving the company's further expansion in the medical device market.
See More
enVVeno Medical Receives FDA Approval for TAVVE Trial
- First IDE Approval: enVVeno Medical has received the first-ever IDE approval from the FDA to conduct the TAVVE® trial, evaluating its innovative enVVe® system aimed at providing the first effective treatment option for approximately 3 million U.S. patients suffering from severe Chronic Venous Insufficiency (CVI), marking a significant advancement in the treatment of deep venous diseases.
- Clinical Trial Scale: The TAVVE trial will be conducted in two phases, with the first phase enrolling 10 patients for a 30-day safety assessment, followed by a second phase enrolling 220 patients, with 165 receiving the enVVe valve and 55 in a control group, expected to provide critical safety and efficacy data to the FDA.
- Significant Market Potential: With U.S. healthcare costs exceeding $20 billion annually due to deep venous insufficiency, the introduction of the enVVe system not only addresses this substantial unmet clinical need but also opens up a multi-billion-dollar market opportunity for the company, enhancing its competitiveness in the medical device sector.
- Sufficient Funding for Operations: As of March 31, 2026, enVVeno has approximately $25 million in cash and investments, which is expected to fund operations into Q3 2027, providing financial support for the successful execution of the TAVVE trial.
See More
enVVeno Medical Reports FY GAAP EPS of -$33.06 Amid Reverse Stock Split
- Poor Financial Performance: enVVeno Medical reported a FY GAAP EPS of -$33.06, indicating significant challenges in financial health that could lead to a decline in investor confidence.
- Reverse Stock Split Announcement: The company announced a reverse stock split aimed at boosting its share price to meet exchange listing requirements; however, this move failed to improve market sentiment, resulting in a 20% drop in share price.
- Negative Market Reaction: Following the reverse split, the stock price fell by 20%, reflecting investor concerns about the company's future prospects, which may impact its ability to raise capital and maintain market competitiveness.
- Need for Strategic Reevaluation: Given the current financial situation, the company must reassess its strategic direction to address ongoing losses and restore investor trust, ensuring sustainable growth in the future.
See More
enVVeno Medical Approves 1-for-35 Reverse Stock Split, Reducing Shares to 655K
- Reverse Stock Split Decision: enVVeno Medical's board approved a 1-for-35 reverse stock split effective January 20, 2026, reducing outstanding shares from approximately 22.9 million to about 655,000, aiming to enhance share price and attract investor interest.
- Exchange Arrangement: Post-split, the company's common stock will resume trading on the Nasdaq Capital Market under the existing ticker symbol 'NVNO', indicating a strategic move to improve market perception and liquidity.
- Market Reaction: Following the reverse split announcement, enVVeno Medical's stock price fell 19.69% in premarket trading to $0.2761, reflecting negative market sentiment that could impact investor confidence.
- Shareholder Impact: The reverse split will consolidate every 35 shares into one, which may reduce the number of shares held by shareholders in the short term, but the company aims to improve long-term investment appeal through a higher share price.
See More
Gold Drops More Than 2%; Cidara Therapeutics Stock Soars
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling 0.44%, while the NASDAQ and S&P 500 rose by 0.59% and 0.27%, respectively. Utilities shares increased slightly, but communication services stocks dropped by 1%.
Notable Company Performances: Spire Inc's shares fell over 2% after reporting larger-than-expected quarterly losses, while Cidara Therapeutics saw a 105% surge in shares following Merck's acquisition announcement.
Commodities Update: Oil prices rose by 1.9% to $59.81, while gold and silver prices fell by 2.2% and 5%, respectively. Copper also saw a decline of 1.1%.
Global Market Trends: European shares declined, with the STOXX 600 down 1.54%, and Asian markets mostly closed lower, highlighted by Japan's Nikkei 225 dropping 1.77%.
See More
